These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15240516)

  • 21. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma.
    Lambooy LH; Gidding CE; van den Heuvel LP; Hulsbergen-van de Kaa CA; Ligtenberg M; Bökkerink JP; De Abreu RA
    Clin Cancer Res; 2003 Feb; 9(2):812-9. PubMed ID: 12576454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma.
    Ifversen MR; Kågedal B; Christensen LD; Rechnitzer C; Petersen BL; Heilmann C
    Int J Oncol; 2005 Jul; 27(1):121-9. PubMed ID: 15942651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome.
    Yang Q; Kiernan CM; Tian Y; Salwen HR; Chlenski A; Brumback BA; London WB; Cohn SL
    Clin Cancer Res; 2007 Jun; 13(11):3191-7. PubMed ID: 17545522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.
    Paydas S; Tanriverdi K; Yavuz S; Disel U; Baslamisli F; Burgut R
    Am J Hematol; 2005 Aug; 79(4):257-61. PubMed ID: 16044453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of n-myc gene amplification in neuroblastoma by comparative, in situ,and real-time polymerase chain reaction.
    Melegh Z; Bálint I; Tóth E; Csernák E; Szentirmay Z; Nagy K
    Pediatr Pathol Mol Med; 2003; 22(3):213-22. PubMed ID: 12746172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
    Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
    Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Clin Cancer Res; 2003 Oct; 9(13):4835-40. PubMed ID: 14581355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
    Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
    Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation.
    Geerts D; Wallick CJ; Koomoa DL; Koster J; Versteeg R; Go RC; Bachmann AS
    Clin Cancer Res; 2007 Nov; 13(21):6312-9. PubMed ID: 17975142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
    Griffioen M; Kessler JH; Borghi M; van Soest RA; van der Minne CE; Nouta J; van der Burg SH; Medema JP; Schrier PI; Falkenburg JH; Osanto S; Melief CJ
    Clin Cancer Res; 2006 May; 12(10):3130-6. PubMed ID: 16707612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MYCN expression in human rhabdomyosarcoma cell lines and tumour samples.
    Toffolatti L; Frascella E; Ninfo V; Gambini C; Forni M; Carli M; Rosolen A
    J Pathol; 2002 Apr; 196(4):450-8. PubMed ID: 11920742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
    Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
    Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens.
    Kalina T; Vaskova M; Mejstrikova E; Madzo J; Trka J; Stary J; Hrusak O
    BMC Cancer; 2005 Apr; 5():38. PubMed ID: 15826304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma.
    Kuroda T; Morikawa N; Matsuoka K; Fujino A; Honna T; Nakagawa A; Kumagai M; Masaki H; Saeki M
    J Pediatr Surg; 2008 Dec; 43(12):2182-5. PubMed ID: 19040931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
    Westermann F; Henrich KO; Wei JS; Lutz W; Fischer M; König R; Wiedemeyer R; Ehemann V; Brors B; Ernestus K; Leuschner I; Benner A; Khan J; Schwab M
    Clin Cancer Res; 2007 Aug; 13(16):4695-703. PubMed ID: 17652624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L1 is associated with favorable outcome in neuroblastomas in contrast to adult tumors.
    Wachowiak R; Fiegel HC; Kaifi JT; Quaas A; Krickhahn A; Schurr PG; Erttmann R; Schachner M; Kluth D; Sauter G; Izbicki JR
    Ann Surg Oncol; 2007 Dec; 14(12):3575-80. PubMed ID: 17917782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expression of PRAME gene in multiple myeloma].
    Abramenko IV; Belous NI; Kriachok IA; Chumak AA; Aksenova EV; Lisovskaia EV; Misiurin AV
    Ter Arkh; 2004; 76(7):77-81. PubMed ID: 15379133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
    Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
    BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.